Indivior Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Indivior de 33.5% y 10.3% por año respectivamente. Se prevé que el BPA crezca en un 32.5% al año. Se espera que la rentabilidad financiera sea de 55.2% en 3 años.

Información clave

34.7%

Tasa de crecimiento de los beneficios

34.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	14.9%
Tasa de crecimiento de los ingresos	10.4%
Rentabilidad financiera futura	85.3%
Cobertura de analistas	Good
Última actualización	06 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

May 03

Previsiones de crecimiento de beneficios e ingresos

LSE:INDV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	1,559	440	474	530	4
12/31/2025	1,423	341	279	288	6
12/31/2024	1,262	268	250	147	6
3/31/2024	1,124	5	-383	-334	N/A
12/31/2023	1,093	2	-368	-315	N/A
9/30/2023	1,042	-235	-89	-52	N/A
6/30/2023	1,002	-59	-22	-11	N/A
3/31/2023	947	-50	23	35	N/A
12/31/2022	901	-53	-9	-4	N/A
9/30/2022	882	166	176	181	N/A
6/30/2022	838	152	160	145	N/A
3/31/2022	818	166	175	189	N/A
12/31/2021	791	205	339	353	N/A
9/30/2021	753	156	101	115	N/A
6/30/2021	725	139	81	115	N/A
3/31/2021	674	95	39	42	N/A
12/31/2020	647	-148	-197	-193	N/A
9/30/2020	595	-190	-84	-82	N/A
6/30/2020	634	-152	-70	-69	N/A
3/31/2020	700	-95	-131	-130	N/A
12/31/2019	785	134	148	151	N/A
9/30/2019	889	213	217	200	N/A
6/30/2019	935	254	281	275	N/A
3/31/2019	988	248	401	413	N/A
12/31/2018	1,005	275	299	303	N/A
9/30/2018	1,033	106	247	276	N/A
6/30/2018	1,064	67	171	210	N/A
3/31/2018	1,083	71	231	260	N/A
12/31/2017	1,093	58	N/A	295	N/A
9/30/2017	1,087	281	N/A	360	N/A
6/30/2017	1,080	81	N/A	409	N/A
3/31/2017	1,065	65	N/A	370	N/A
12/31/2016	1,058	35	N/A	407	N/A
9/30/2016	1,047	-6	N/A	326	N/A
6/30/2016	1,028	191	N/A	283	N/A
3/31/2016	1,021	201	N/A	252	N/A
12/31/2015	1,014	228	N/A	320	N/A
9/30/2015	1,037	268	N/A	300	N/A
6/30/2015	1,058	314	N/A	369	N/A
3/31/2015	1,085	361	N/A	530	N/A
12/31/2014	1,115	403	N/A	440	N/A
9/30/2014	1,147	443	N/A	572	N/A
12/31/2013	1,216	489	N/A	791	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (33.5% al año) de INDV es superior a la tasa de ahorro (1.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (33.5% al año) de INDV crezcan más rápidamente que el mercado UK (12.2% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de INDV crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (10.3% al año) de INDV crezcan más rápidamente que los del mercado UK (3.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 10.3% al año) de INDV crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de INDV sea muy elevada dentro de 3 años (55.2%).

Indivior Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Indivior plc Reconfirms Earnings Guidance for 2024

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Indivior PLC Provides Revenue Guidance for the Full Year

Recent updates

Indivior PLC Announces Board Committee Changes

Shareholders May Not Be So Generous With Indivior PLC's (LON:INDV) CEO Compensation And Here's Why

Indivior plc Reconfirms Earnings Guidance for 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024

Indivior PLC to Report First Half, 2024 Results on Jul 25, 2024

CEO & Executive Director recently sold UK£1.5m worth of stock

Indivior PLC Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

Chief Human Resources Officer recently sold UK£1.8m worth of stock

The Market Lifts Indivior PLC (LON:INDV) Shares 26% But It Can Do More

Full year 2023 earnings released: EPS: US$0.015 (vs US$0.38 loss in FY 2022)

Indivior PLC to Report Q4, 2023 Results on Feb 22, 2024

Are Investors Undervaluing Indivior PLC (LON:INDV) By 50%?

Indivior PLC (LSE:INDV) announces an Equity Buyback for 13,631,504 shares, for $100 million.

Indivior PLC Provides Earnings Guidance for the Fiscal Year 2023

New major risk - Financial position

Third quarter 2023 earnings released: US$0.98 loss per share (vs US$0.29 profit in 3Q 2022)

Indivior PLC Announces Executive Changes

Indivior plc Provides Revenue Guidance for the Third Quarter and Year to Date 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC to Report Q3, 2023 Results on Nov 09, 2023

Two Seas Capital Provides Information to Shareholders of Indivior PLC

Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023

Indivior PLC Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.28 (vs US$0.34 in 2Q 2022)

Indivior PLC to Report Q2, 2023 Results on Jul 27, 2023

Indivior PLC to Report First Half, 2023 Results on Jul 27, 2023

We Think Indivior (LON:INDV) Can Stay On Top Of Its Debt

Indivior PLC Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl

Chief Manufacturing & Supply Officer recently sold UK£1.7m worth of stock

Indivior (LON:INDV) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS misses analyst expectations

Full year 2022 earnings: Revenues in line with analyst expectations

Indivior PLC Announces Board and Committee Changes

Indivior PLC to Report Q4, 2022 Results on Feb 16, 2023

Indivior PLC Reiterates Earnings Guidance for the Fiscal Year 2022

Here's Why Indivior (LON:INDV) Can Manage Its Debt Responsibly

High number of new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Third quarter 2022 earnings released: EPS: US$0.29 (vs US$0.18 in 3Q 2021)

Aquestive Therapeutics Announces Positive Decision in States' Suboxone Antitrust Lawsuit on All Claims

Indivior PLC to Report Q3, 2022 Results on Oct 27, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC, Annual General Meeting, Sep 30, 2022

Indivior PLC Publishes Exploratory Study Showing That Access to Medication for Opioid Use Disorder Varies Across Organized Health Systems in the U.S

Indivior PLC Provides Revenue Guidance for the Full Year

Indivior plc Announces Executive Changes

Second quarter 2022 earnings released: EPS: US$0.07 (vs US$0.084 in 2Q 2021)

Indivior (LON:INDV) Seems To Use Debt Quite Sensibly

Indivior PLC to Report Q2, 2022 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Indivior Names Nina DeLorenzo Chief Global Impact Officer

Investor sentiment deteriorated over the past week

Indivior Announces First Patient Included in Aelis Farma's Phase 2B Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects with Moderate to Severe Cannabis Use Disorder

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022

High number of new directors

Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC

Indivior PLC Publishes Modeling Data Showing Buprenorphine May Mitigate Fentanyl-Induced Respiratory Depression in Chronic Opioid Users

Investor sentiment improved over the past week

Consensus forecasts updated

Indivior PLC, Annual General Meeting, May 05, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Indivior PLC, Annual General Meeting, May 05, 2022

Chief Human Resources Officer recently sold UK£428k worth of stock

Chief Scientific Officer exercised options and sold UK£1.5m worth of stock

Chief Commercial & Strategy Officer recently sold UK£810k worth of stock